Abstract
Cyclosaligenyl-2′,3′-didehydro-2′,3′-dideoxythymidine-5′-monophosphate (cycloSal-d4TMP) is a potent and selective inhibitor of human immunodeficiency virus replication in cell culture and differs from other nucleotide prodrug approaches in that it is designed to selectively deliver the nucleotide 5′-monophosphate by a controlled, chemically induced hydrolysis. Its antiviral efficacy in cell culture is at least as good as, if not superior to, that of d4T. CycloSal-d4TMP was found to lead to the efficient intracellular release of d4TMP in a variety of cell lines, including both wild-type CEM and thymidine kinase-deficient CEM/TK− cells. Under similar experimental conditions, exposure of CEM/TK− cells to d4T failed to result in significant d4TTP levels. The intracellular conversion of cycloSal-d4TMP proved to be both time and dose dependent. The half-life of d4TTP generated intracellularly from d4T- or cycloSal-d4TMP-treated CEM cells was ∼3.5 h, and the intracellular ratios of d4TTP/d4TMP in cells exposed to cycloSal-d4TMP gradually increased from 1 to 3.4 upon prolonged incubation. Radiolabeled cycloSal-d4TMP could be separated as its two R p and S pdiastereomers on high-performance liquid chromatography. TheR p diastereomer of cycloSal-d4TMP was 3- to 7-fold more efficient in releasing d4TMP and generating d4TTP than theS p cycloSal-d4TMP diastereomer. This correlated well with the 5-fold more pronounced antiviral activity of the R p diastereomer versus theS p diastereomer. d4TMP is a poor substrate for the cytosolic 5′(3′)-deoxyribonucleotidase (V max/K m for d4TMP: 0.08 ofV max/K m for dTMP) and is only slowly hydrolyzed to d4T. This contributes to the efficient conversion of the prodrug of d4TTP.
Footnotes
- Received February 28, 2000.
- Accepted July 6, 2000.
-
Send reprint requests to: Jan Balzarini, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium. E-mail:jan.balzarini{at}rega.kuleuven.ac.be
-
This work was supported by the Biomedical Research Program of the European Commission, the Belgian Geconcerteerde Onderzoeksacties (project 00/12), and the Fonds voor Wetenschappelijk Onderzoek—Vlaanderen (project G.0104.98). Work in V.B.'s laboratory was supported by the Instituto Superiore di Sanitá, AIDS Project, and by the Italian Association for Cancer Research.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
In this issue
Cyclosaligenyl-2′,3′-didehydro-2′,3′-dideoxythymidine Monophosphate: Efficient Intracellular Delivery of d4TMP
